Clinical TrialApr 30, 2026, 07:02 AM
ACIU Initiates Final ABATE Trial Cohort; Triggers $12M Takeda Milestone
AI Summary
AC Immune SA announced the dosing of the first patients in Cohort AD4, the final cohort of its Phase 1b/2 ABATE trial for ACI-24, an active immunotherapy targeting Alzheimer's disease. This milestone triggered a $12 million payment from Takeda under their exclusive partnership agreement. The trial aims to evaluate ACI-24's potential for precision prevention of neurodegenerative diseases, building on encouraging early safety and immunogenicity data from previous cohorts. Data from Cohorts AD1, AD2, and AD3 are anticipated in Q2 2026.
Key Highlights
- ACIU initiated the final Cohort AD4 in its Phase 1b/2 ABATE trial for ACI-24, an Alzheimer's disease treatment.
- The initiation of Cohort AD4 triggered a $12 million milestone payment from Takeda.
- ACI-24 is an anti-Abeta active immunotherapy designed to induce antibody response against toxic Abeta forms.
- Data from previous ABATE Cohorts AD1, AD2, and AD3 (74 patients) showed ACI-24 is safe and immunogenic.
- 12-month treatment data from Cohorts AD1, AD2, and AD3 are expected in Q2 2026.
- Cohort AD4 will initially include 36 patients, with potential expansion to approximately 112 patients.
- AC Immune is eligible for up to $2.1 billion in additional milestones and tiered double-digit royalties from Takeda.